Katharina Cand.Med. Karsch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Katharina Cand.Med. Karsch has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Rath
Vaccine Safety Initiative, 10437 Berlin, Germany
2 shared publications - Brunhilde Schweiger
National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany
2 shared publications - Franziska Cand.Med. Tief
Division of Pneumonology-Immunology, Department of Pediatrics, Charité University Medical Center, Augustenburger Platz 1, 13353 Berlin, Germany
2 shared publications - Susann Cand.Med. Muehlhans
Division of Pneumonology-Immunology, Department of Pediatrics, Charité University Medical Center, Augustenburger Platz 1, 13353 Berlin, Germany
2 shared publications - Anja Weick
Division of Pneumonology-Immunology, Department of Pediatrics, Charité University Medical Center, Augustenburger Platz 1, 13353 Berlin, Germany
1 shared publication - Christian Peiser
Division of Pneumonology-Immunology, Department of Pediatrics, Charité University Medical Center, Augustenburger Platz 1, 13353 Berlin, Germany
1 shared publication
Latest Publications
- 1 March 2015
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 81 (3) , 171-176
Evaluation of novel second-generation RSV and influenza rapid tests at the point of care
- 1 March 2015
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 81 (3) , 171-176
Evaluation of novel second-generation RSV and influenza rapid tests at the point of care
- 1 September 2012
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 31 (9) , 899-905
Virus Load Kinetics and Resistance Development During Oseltamivir Treatment in Infants and Children Infected With Influenza A(H1N1) 2009 and Influenza B Viruses
Background: Infants and small children are the most effective transmitters of influenza, while bearing a high risk of hospitalization and adverse disease outcomes. This study aims to investigate virus load kinetics and resistance development during oseltamivir therapy in infants and children infected with influenza A(H1N1) 2009 and influenza B viruses. Methods: Virus load in nasopharyngeal samples and phenotypic/genotypic neuraminidase inhibitor resistance were determined at baseline, at day 5 and in additional follow-up samples, if available. Patient-specific viral clearance indices CLν(i) were determined along with estimates of the time required to achieve nondetectable virus load. Results: No evidence of baseline oseltamivir resistance was detected in 36 patients infected with influenza A(H1N1) 2009 (n = 27) or influenza B (Victoria, Yamagata; n = 9) before oseltamivir therapy. On average, viral loads were lower for influenza type B (median = 5.9·103/mL) than for drug-resistant (median = 2.6·106/mL) and sensitive A(H1N1) 2009 (median = 4.8·104/mL), P = 0.04 and P = 0.09, respectively. Time required to achieve nondetectable virus load was significantly longer in drug-resistant A(H1N1) 2009 (median 15.4 days) compared with drug-sensitive A(H1N1) 2009 (P = 0.003; median 7.7 days) and drug-sensitive influenza B (P = 0.001; median 5 days). No evidence of viral rebound was observed once viral clearance was achieved. Conclusions: Our data indicate that influenza subtyping in combination with baseline viral load measurements might help to optimize the duration of antiviral therapy in the individual child. Lower than expected virologic response rates in patients without malabsorption or compliance issues may suggest resistance development.
- 1 September 2012
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 31 (9) , 899-905
Virus Load Kinetics and Resistance Development During Oseltamivir Treatment in Infants and Children Infected With Influenza A(H1N1) 2009 and Influenza B Viruses
Background: Infants and small children are the most effective transmitters of influenza, while bearing a high risk of hospitalization and adverse disease outcomes. This study aims to investigate virus load kinetics and resistance development during oseltamivir therapy in infants and children infected with influenza A(H1N1) 2009 and influenza B viruses. Methods: Virus load in nasopharyngeal samples and phenotypic/genotypic neuraminidase inhibitor resistance were determined at baseline, at day 5 and in additional follow-up samples, if available. Patient-specific viral clearance indices CLν(i) were determined along with estimates of the time required to achieve nondetectable virus load. Results: No evidence of baseline oseltamivir resistance was detected in 36 patients infected with influenza A(H1N1) 2009 (n = 27) or influenza B (Victoria, Yamagata; n = 9) before oseltamivir therapy. On average, viral loads were lower for influenza type B (median = 5.9·103/mL) than for drug-resistant (median = 2.6·106/mL) and sensitive A(H1N1) 2009 (median = 4.8·104/mL), P = 0.04 and P = 0.09, respectively. Time required to achieve nondetectable virus load was significantly longer in drug-resistant A(H1N1) 2009 (median 15.4 days) compared with drug-sensitive A(H1N1) 2009 (P = 0.003; median 7.7 days) and drug-sensitive influenza B (P = 0.001; median 5 days). No evidence of viral rebound was observed once viral clearance was achieved. Conclusions: Our data indicate that influenza subtyping in combination with baseline viral load measurements might help to optimize the duration of antiviral therapy in the individual child. Lower than expected virologic response rates in patients without malabsorption or compliance issues may suggest resistance development.